Mismatched cord blood stem cells meet need for urgent Rx in acute leukemia

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

SAN FRANCISCO-Mismatched cord blood can be a suitable alternative for stem cell transplants for patients with acute leukemia, especially in emergency situations, according to research presented at ASH 2008.

SAN FRANCISCO-Mismatched cord blood can be a suitable alternative for stem cell transplants for patients with acute leukemia, especially in emergency situations, according to research presented at ASH 2008.

The study of bone marrow stem cell transplants in 1,240 adults with acute leukemia revealed that rates of transplant-related deaths, leukemia-free survival, and overall survival were similar for mismatched peripheral blood, bone marrow, and cord blood transplants. Among patients with cord blood transplants, there was also less chronic graft -vs-host disease than from mismatched peripheral blood and bone marrow transplants (abstract 151).

“The chance of finding a matched donor among Caucasians is just 50%, if there’s no matched sibling donor, and the rates are even lower for minorities. For instance, the rate of matched unrelated donors among African Americans is 17%,” said lead researcher Mary Eapen, MBBS, an associate professor of pediatrics at the Medical College of Wisconsin in Milwaukee. “What this study showed is that for those patients who don’t have an available matched donor, cord blood is a suitable option.”

The study analyzed the outcomes of 707 patients with acute myeloid leukemia and 533 patients with acute lymphocytic leukemia who received stem cell transplants from 2002 to 2006, using registry data from the National Marrow Donor Program. The study evaluated the efficacy of three types of stem cell sources: bone marrow, peripheral blood, and cord blood.

Among patients who received a bone marrow stem cell transplant, 243 were matched at eight out of eight possible HLA loci and 111 were matched at seven HLA loci. In those receiving a peripheral blood stem cell transplant, 518 were matched at eight HLA loci and 210 at seven HLA loci. For those receiving cord blood transplants, 28 were matched at five or six HLA loci and 110 at four HLA loci.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma